Granules India appoints Dr PN Baskaran as President - Head API Manufacturing, Operations

Published On 2025-03-26 07:05 GMT   |   Update On 2025-03-26 07:05 GMT

Telangana: Granules India has announced the appointment of Dr P.N. Baskaran as President - Head API Manufacturing & Operations with effect from April 02, 2025.

"This is to inform you that Dr. P.N. Baskaran has been appointed as President - Head API Manufacturing & Operations with effect from April 02, 2025 and has been designated as one of the SMPs of the Company," Granules stated in a BSE filling.
Dr. PN Baskaran has a Doctorate in Chemical Engineering from Annamalai University with over 30 years of leadership experience in Operations Management, specialising in Manufacturing, Supply Chain, Quality, Projects, EHS, and Operational Excellence. He is a proven leader, trained through various leadership programs and development centres, in various reputed organizations. He was instrumental in various automation and digitisation programs in his previous experiences. Dr. Baskaran brings deep expertise in API, PFI, and Formulation business for various markets from small to large volumes, high potent to oncology, and low to high margin products.
Medical Dialogues team had earlier reported that Sethu Madhavan Sankaran had resigned from the position of Senior Vice President & Head-API Manufacturing & Operations of Granules India.

Sethu Madhavan is a postgraduate in chemical engineering from ICT Mumbai and an executive MBA from MDI Gurgaon. He has over 27 years of experience in API manufacturing across biologics and small molecules and has worked with organizations like Biocon, Teva API, Ranbaxy, Dr. Reddy’s Laboratories & Herdilla Chemicals. He has handled various functions like R&D, Operations, Technical Services & Technology Transfer, and Operational Excellence activities in the pharmaceutical industry. He joined Granules India in March 2024.

Granules India Limited, incorporated in 1991 is a vertically integrated Indian pharmaceutical company headquartered in Hyderabad. Amongst the few pharmaceutical companies in the world to be present across the manufacturing of the entire pharmaceutical value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs), Granules products are distributed to over 300+ customers in regulated and semiregulated markets with a global presence extending to over 80+ countries with offices across India, US and UK. The Company has 10 manufacturing facilities out of which 8 are located in India and 2 are in the USA and has regulatory approvals from the US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC, and HALAL.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News